Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

AUPH - Aurinia Pharmaceuticals Inc Stock Price, Fair Value and News

$12.01-0.21 (-1.72%)
Delayed as of 19 Aug 2025, 11:02 am ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

AUPH Price Action

Last 7 days

6.9%

Last 30 days

41.6%

Last 90 days

47.2%

Trailing 12 Months

95.2%

AUPH Stock Price

Sep'24Dec'24Mar'25Jun'254681012
$12.22

AUPH RSI Chart

NovDec2025FebMarAprMayJunJulAug102030405060708090

AUPH Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

26.53

Price/Sales (Trailing)

6.18

EV/EBITDA

18.98

Price/Free Cashflow

17.35

AUPH Price/Sales (Trailing)

202320242025010203040

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AUPH Fundamentals

AUPH Revenue

Revenue (TTM)

260.1M

Rev. Growth (Yr)

22.41%

Rev. Growth (Qtr)

12.08%

2018202020222024050M100M150M200M250M

AUPH Earnings

Earnings (TTM)

60.6M

Earnings Growth (Yr)

2.9K%

Earnings Growth (Qtr)

-7.84%

2018202020222024-200M-150M-100M-50M050M

AUPH Profitability

Operating Margin

89.51%

EBT Margin

24.02%

Return on Equity

18.08%

Return on Assets

12.07%

Free Cashflow Yield

5.76%

AUPH Investor Care

Buy Backs (1Y)

7.95%

Diluted EPS (TTM)

0.43

AUPH Alerts

Revenue Breakdown

As of: Jun 30, 2025
2022202320242025010M20M30M40M50M60M70M
Product
ProductValuePercent
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
201720182019202020212022202320242025050M100M150M200M250M
Net sales
YearQ1Q2Q3Q4
2025247.3M260.1M00
2024191.4M207.1M220.4M235.1M
2023146.8M160.1M158.9M175.5M
202266.3M87.9M129.0M134.0M
202149.0M47.9M46.7M45.6M
2020318.0K318.0K25.2M50.1M
2019426.8K390.5K354.3K318.0K
2018429.3K440.5K451.8K463.0K
2017000418.0K
2016000173.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
 CEO
 WEBSITEauriniapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES300

Aurinia Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Aurinia Pharmaceuticals Inc? What does AUPH stand for in stocks?

AUPH is the stock ticker symbol of Aurinia Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aurinia Pharmaceuticals Inc (AUPH)?

As of Mon Aug 18 2025, market cap of Aurinia Pharmaceuticals Inc is 1.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AUPH stock?

You can check AUPH's fair value in chart for subscribers.

Is Aurinia Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AUPH is over valued or under valued. Whether Aurinia Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Aurinia Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AUPH.

What is Aurinia Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Aug 18 2025, AUPH's PE ratio (Price to Earnings) is 26.53 and Price to Sales (PS) ratio is 6.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aurinia Pharmaceuticals Inc's stock?

In the past 10 years, Aurinia Pharmaceuticals Inc has provided 0.144 (multiply by 100 for percentage) rate of return.